SYSTM Wealth Solutions LLC Sells 336 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

SYSTM Wealth Solutions LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,852 shares of the biopharmaceutical company’s stock after selling 336 shares during the period. SYSTM Wealth Solutions LLC’s holdings in Gilead Sciences were worth $127,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GILD. E Fund Management Co. Ltd. raised its stake in Gilead Sciences by 58.8% in the second quarter. E Fund Management Co. Ltd. now owns 32,444 shares of the biopharmaceutical company’s stock valued at $2,226,000 after buying an additional 12,018 shares during the last quarter. Wealth Alliance raised its position in shares of Gilead Sciences by 40.3% in the 2nd quarter. Wealth Alliance now owns 19,905 shares of the biopharmaceutical company’s stock valued at $1,366,000 after purchasing an additional 5,716 shares during the last quarter. Bradley Foster & Sargent Inc. CT boosted its stake in Gilead Sciences by 1.7% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 39,381 shares of the biopharmaceutical company’s stock worth $2,702,000 after purchasing an additional 642 shares in the last quarter. Mutual of America Capital Management LLC grew its position in Gilead Sciences by 0.3% during the 2nd quarter. Mutual of America Capital Management LLC now owns 179,205 shares of the biopharmaceutical company’s stock worth $12,295,000 after purchasing an additional 580 shares during the last quarter. Finally, Axxcess Wealth Management LLC increased its stake in Gilead Sciences by 10.2% during the 2nd quarter. Axxcess Wealth Management LLC now owns 19,746 shares of the biopharmaceutical company’s stock valued at $1,355,000 after purchasing an additional 1,830 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $83.90 on Friday. The stock has a market capitalization of $104.53 billion, a price-to-earnings ratio of 233.06, a PEG ratio of 2.80 and a beta of 0.18. The stock has a 50-day moving average of $76.67 and a 200 day moving average of $71.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analyst Ratings Changes

GILD has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and set a $95.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 11th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Truist Financial lifted their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a research report on Monday, July 8th. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.06.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,002,940 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.